Incyte Corporation
INCY
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor tā¦ read more
Healthcare
Biotechnology
32 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$94.12
Price+4.20%
$3.79
1Y
Price
Market Cap
$18.731b
Large
Price/Earnings 3y Avg5y Avg
14.7x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+27.5%
EBITDA Margin+19.9%
Net Profit Margin+34.6%
Free Cash Flow Margin+27.5%
EBITDA Margin+19.9%
Net Profit Margin+34.6%
Free Cash Flow MarginRevenue
$5.141b
+21.2%
1y CAGR+15.0%
3y CAGR+14.6%
5y CAGREarnings
$1.287b
+3845.0%
1y CAGR+1275.3%
3y CAGR+940.4%
5y CAGREPS
$6.41
+4173.3%
1y CAGR+1384.4%
3y CAGR+1022.2%
5y CAGRBook Value
$5.167b
$6.958b
Assets$1.803b
Liabilities$69.428m
DebtDebt to Assets
1.0%
-
Debt to EBITDAFree Cash Flow
$1.355b
+443.9%
1y CAGR+116.6%
3y CAGR+101.6%
5y CAGRNo items found.
Press Releases
Statements and updates from the company